Education and Training
2012  PhD (Clinical and Experimental Therapeutics), University of Kentucky
2007 - 2008   PGY-1 Pharmacy Practice Residency, University of Kentucky HealthCare
2007  PharmD, The University of Iowa
2003  BS (Biology), The University of Iowa

Certification and Licensure
2011  Graduate Certificate in Clinical and Translational Science, University of Kentucky
2008  Scholarship of Teaching and Learning Certificate, University of Kentucky
2007 - present  Pharmacist licensure, Kentucky

Research Interests
Dr. Brogden is both a clinical pharmacist and pharmaceutical scientist. Her research program explores the skin as a means of drug delivery, and as a portal for understanding underlying pathologic processes within the body. Dr. Brogden’s laboratory provides a translational and interdisciplinary setting in which clinical and laboratory research intersect, allowing a fluid transition between benchtop, animal, and human studies. Specifically, the following areas are currently being explored. 

  1. Development of microneedle delivery techniques for patients with challenging drug delivery needs, focusing primarily on pediatric and geriatric populations.
  2. Formulation of innovative cutaneous drug preparations for treatment of localized skin disorders. 
  3. Elucidation of age-related changes in skin barrier and mediator expression as related to immunosenescence and the development of age-related dermatology conditions.

Key words: transdermal, microneedle, skin, percutaneous drug delivery

Honors and Awards
2012-2013 New Investigator Award from the American Association of Colleges of Pharmacy
2013​ Women of Innovation Award (Research Innovation and Leadership category),Technology Association of Iowa Principal Financial Group

  1. Kinn PM, Holdren GO, Westermeyer BA, Abuissa M, Fischer CL, Fairley JA, Brogden KA, Brogden NK. (2015) Age-dependent variation in cytokines, chemokines, and biologic analytes rinsed from the surface of healthy human skin. Scientific Reports. Accepted for publication.
  2. Holdren GO, Rosenthal DJ, Yang J, Bates AM, Fischer CL, Zhang Y, Brogden NK, and Brogden KA. (2014) Antimicrobial activity of chemokine CXCL10 for dermal and oral microorganisms. Antibiotics. 3(4):527-539.
  3. Kelchen MN, Holdren GO, Farley MJ, Zimmerman BM, Fairley JA, Brogden NK. (2014) Optimization of impedance spectroscopy techniques for measuring cutaneous micropore formation after microneedle treatment in an elderly population. Pharmaceutical Research. Dec;31(12):3478-86.
  4. Ghosh P, Brogden NK, Stinchcomb AL. (2014) Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle treated skin. Journal of Pharmaceutical Sciences. Feb;103(2):652-60. PMID: 24395718 
  5. Milewski M, Paudel KS, Brogden NK, Ghosh P, Banks SL, Hammell DC, Stinchcomb AL. (2013) Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in Yucatan minipig: In vitro-in vivo correlation. Molecular Pharmaceutics.Oct 7;10(10):3745-3757. PMID: 24053426 
  6. Brogden NK, Banks SL, Crofford LJ, Stinchcomb AL. (2013) Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Pharmaceutical Research. Aug;30(8):1947-55. PMID: 23761054 
  7. Brogden NK, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. (2013) Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion. Journal of Pharmaceutical Sciences. Jun;102(6):220-9. PMID: 23589356 
  8. Ghosh P, Brogden NK, Stinchcomb AL. (2013) Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery. Molecular Pharmaceutics. Jun 3;10(5):2331-9. PMID: 23590208 
  9. Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. (2012) Diclofenac delays micropore closure following microneedle treatment in human subjects. Journal of Controlled Release. Aug;16(3):220-9. PMID: 22929967
  10. Brogden NK, Mehalick L, Fischer CL, Wertz PW, Brogden KA. (2012) Review - The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacology and Physiology. April;25(4):167-81. PMID: 22538862
  11. Brogden NK, Brogden KA. (2011) Review - Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? International Journal of Antimicrobial Agents. Sept; 38(3):217-25. PMID: 21733662
  12. Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. (2011) Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharmaceutical Research. 28(5):1211-9, May 2011. PMID: 21301935
  13. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. (2010) Challenges and opportunities in transdermal delivery. Therapeutic Delivery. 1(1):109-131, July 2010. PMID: 21132122; PMCID: PMC2995530. 
  14. Banks SL, Pinninti RR, Gill HS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. (2010) Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs in vivo. Journal of Pharmaceutical Sciences. 99(7):3072-80, July 2010. PMID: 20166200, PMCID: PMC2862091
  15. Milewski M, Brogden NK, Stinchcomb AL. (2010) Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opinion on Drug Delivery. 7(5):617-29, May 2010. PMID: 20205604, PMCID: PMC2858255
  16. Florang VF, Rees JR, Brogden NK, Anderson DG, Hurley TD, Doorn JA. (2007)  Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology. 28(1):76-82, Jan 2007. PMID: 16956664 
Person Reference: 
Nicole K Brogden